Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated…

Posted: January 27, 2025 at 2:49 am

Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data

Read the original:
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated...

Related Posts